As one of the most common proto-oncogenes in AML, a gain of function in KRAS/NRAS could activate the pathway of RAS/MAPK, and further lead to overexpression and increased stability of MCL-1 protein, which also plays a major role in VEN-resistance. The gene discussed is KRAS; the disease is acute myeloid leukemia.